Companies
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale.
Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
As the Company continues to build out a global infrastructure decision was made in March 2021 to centralize and build out many of the functions from start within the Moderna Enterprise Solution (MESH) Hub structure which is a GBS organization of Moderna.
The key areas of build up and operations include finance, procurement, pharmacovigilance and medical safety, regulatory, supply chain, digital/IT, HR, legal, project and service management. The Hub started with with first hires in September 2021.
The MESH Hub provides new capabilities and capacity to help meet the growing demand of Moderna’s global business operations.
Additionally, it plays a key role in providing business insights while improving, simplifying, and standardizing processes.
